STOCK TITAN

Esperion Appoints Robert E. Hoffman to Board of Directors

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management

Esperion (NASDAQ: ESPR) has announced significant changes to its Board of Directors. Robert E. Hoffman has been appointed as an independent director, effective immediately, and will serve as Chairperson of the Audit Committee starting May 29, 2025. Nicole Vitullo and Antonio M. Gotto, Jr., M.D., D. Phil. will step down from the board effective June 1, 2025.

Hoffman brings extensive experience in the biopharmaceutical sector, having served as President, CEO, interim CFO, and Chairperson at Kintara Therapeutics (2021-2024). His previous roles include senior positions at Heron Therapeutics, AnaptysBio, and Arena Pharmaceuticals. He currently serves on the boards of TuHURA Biosciences and Fibrobiologics, and has been a board member for several public and private life sciences companies.

Esperion (NASDAQ: ESPR) ha annunciato significative modifiche al suo Consiglio di Amministrazione. Robert E. Hoffman è stato nominato direttore indipendente, con effetto immediato, e assumerà la carica di Presidente del Comitato di Revisione a partire dal 29 maggio 2025. Nicole Vitullo e Antonio M. Gotto, Jr., M.D., D. Phil. lasceranno il consiglio con effetto dal 1° giugno 2025.

Hoffman porta con sé una vasta esperienza nel settore biofarmaceutico, avendo ricoperto i ruoli di Presidente, CEO, CFO ad interim e Presidente presso Kintara Therapeutics (2021-2024). Le sue esperienze precedenti includono posizioni di alto livello presso Heron Therapeutics, AnaptysBio e Arena Pharmaceuticals. Attualmente è membro dei consigli di amministrazione di TuHURA Biosciences e Fibrobiologics, ed è stato membro del consiglio per diverse aziende di scienze della vita pubbliche e private.

Esperion (NASDAQ: ESPR) ha anunciado cambios significativos en su Junta Directiva. Robert E. Hoffman ha sido nombrado director independiente, con efecto inmediato, y asumirá el cargo de Presidente del Comité de Auditoría a partir del 29 de mayo de 2025. Nicole Vitullo y Antonio M. Gotto, Jr., M.D., D. Phil. dejarán la junta con efecto el 1 de junio de 2025.

Hoffman aporta una amplia experiencia en el sector biofarmacéutico, habiendo ocupado los cargos de Presidente, CEO, CFO interino y Presidente en Kintara Therapeutics (2021-2024). Sus roles anteriores incluyen posiciones de alto nivel en Heron Therapeutics, AnaptysBio y Arena Pharmaceuticals. Actualmente, forma parte de los consejos de TuHURA Biosciences y Fibrobiologics, y ha sido miembro de la junta en varias empresas de ciencias de la vida, tanto públicas como privadas.

Esperion (NASDAQ: ESPR)은 이사회에 중대한 변화를 발표했습니다. 로버트 E. 호프만이 독립 이사로 즉시 임명되었으며, 2025년 5월 29일부터 감사위원회 의장을 맡게 됩니다. 니콜 비툴로와 안토니오 M. 고토 주니어, M.D., D. Phil.은 2025년 6월 1일부로 이사직에서 물러납니다.

호프만은 Kintara Therapeutics(2021-2024)에서 사장, CEO, 임시 CFO 및 의장을 역임하며 생명공학 분야에서 폭넓은 경험을 쌓았습니다. 이전에는 Heron Therapeutics, AnaptysBio 및 Arena Pharmaceuticals에서 고위직을 맡았습니다. 현재 TuHURA Biosciences와 Fibrobiologics의 이사회에서 활동하고 있으며, 여러 공공 및 민간 생명과학 회사의 이사로 재직한 경험이 있습니다.

Esperion (NASDAQ: ESPR) a annoncé des changements significatifs au sein de son Conseil d'Administration. Robert E. Hoffman a été nommé directeur indépendant, avec effet immédiat, et assumera le poste de Président du Comité d'Audit à partir du 29 mai 2025. Nicole Vitullo et Antonio M. Gotto, Jr., M.D., D. Phil. quitteront le conseil avec effet au 1er juin 2025.

Hoffman apporte une vaste expérience dans le secteur biopharmaceutique, ayant occupé les postes de Président, CEO, CFO par intérim et Président chez Kintara Therapeutics (2021-2024). Ses précédents rôles incluent des postes de direction chez Heron Therapeutics, AnaptysBio et Arena Pharmaceuticals. Il siège actuellement aux conseils d'administration de TuHURA Biosciences et Fibrobiologics, et a été membre du conseil d'administration de plusieurs entreprises de sciences de la vie, tant publiques que privées.

Esperion (NASDAQ: ESPR) hat bedeutende Änderungen in seinem Vorstand angekündigt. Robert E. Hoffman wurde mit sofortiger Wirkung als unabhängiger Direktor ernannt und wird ab dem 29. Mai 2025 als Vorsitzender des Prüfungsausschusses fungieren. Nicole Vitullo und Antonio M. Gotto, Jr., M.D., D. Phil. werden mit Wirkung zum 1. Juni 2025 aus dem Vorstand ausscheiden.

Hoffman bringt umfangreiche Erfahrungen im biopharmazeutischen Sektor mit, da er von 2021 bis 2024 Präsident, CEO, interimistischer CFO und Vorsitzender bei Kintara Therapeutics war. Zu seinen früheren Positionen gehören leitende Funktionen bei Heron Therapeutics, AnaptysBio und Arena Pharmaceuticals. Derzeit ist er Mitglied der Vorstände von TuHURA Biosciences und Fibrobiologics und war Mitglied des Vorstands mehrerer öffentlicher und privater Unternehmen im Bereich der Lebenswissenschaften.

Positive
  • Appointment of experienced financial executive with extensive biotech industry expertise
  • New director brings significant commercialization and financial oversight experience
  • Addition of audit committee leadership strengthens financial governance
Negative
  • Loss of two experienced board members could create temporary leadership gap
  • Transition period in board composition may affect strategic continuity

- Veteran Industry Executive Brings Decades of Financial and Leadership Experience -

ANN ARBOR, Mich., April 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Robert E. Hoffman as an independent director, effective immediately, and he will also serve as Chairperson of the Audit Committee effective May 29, 2025. In addition, the Company announced that Nicole Vitullo and Antonio M. Gotto, Jr., M.D., D. Phil. will step down from the board of directors, effective June 1, 2025.

“We are pleased to welcome Robert to the Esperion Board, confident that his decades of leadership within the biopharmaceutical sector will be of great benefit as we engage in our commercialization efforts and expand our pipeline of next generation ACLY inhibitors,” said Sheldon Koenig, President and CEO of Esperion. “Robert is a well-regarded and skilled leader who brings a wealth of insights from his tenure in the sector. I am confident his deep domain expertise in the commercialization of medicines will be a valued resource as we continue to mature as a commercial organization.”

Mr. Koenig continued, “I extend my deep gratitude to Nicole and Dr. Gotto for their innumerable contributions and years of dedication to Esperion. We thank them for their service and wish them both the very best in their future endeavors.”

“I am delighted to have the opportunity to work closely with the Esperion team at this important time of its growth as a commercial organization,” said Mr. Hoffman. “I look forward to partnering with management and the board to support Esperion in their mission to bring new medicines to market to address the unmet cardiometabolic needs of patients and healthcare professionals.”

Mr. Hoffman served as President, CEO, interim Chief Financial Officer and Chairperson of the board of directors of Kintara Therapeutics, Inc. from 2021 to 2024. Mr. Hoffman previously served as Senior Vice President and Chief Financial Officer of Heron Therapeutics, Inc. from 2017 to 2020, and as Chief Financial Officer of AnaptysBio, Inc. from 2015 to 2016. From 2012 to 2015, Mr. Hoffman served as the Senior Vice President, Finance and Chief Financial Officer of Arena Pharmaceuticals, Inc. (“Arena”) until its sale to Pfizer in 2022 and held several roles of increasing responsibility at Arena from 1997 to 2011.

Mr. Hoffman serves as a member of the steering committee of the Association of Bioscience Financial Officers. He formerly served as a director and President of the San Diego Chapter of Financial Executives International and was an advisor to the Financial Accounting Standard Board, from 2010 to 2020.

Mr. Hoffman currently serves on the board of directors of TuHURA Biosciences and Fibrobiologics, Inc. and has served as a member of the board of directors of several public and private life sciences companies, including ASLAN Pharmaceuticals Limited, Saniona AB, Kura Oncology, Inc., CombiMatrix Corporation, MabVax Therapeutics Holdings, Inc., and Aravive, Inc.

Mr. Hoffman holds a B.B.A. from St. Bonaventure University.

About Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.

Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.

Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, future operations, commercial products, clinical development, including the timing, designs and plans for the CLEAR Outcomes study and its results, plans for potential future product candidates, financial condition and outlook, including expected cash runway, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion’s actual results to differ significantly from those projected, including, without limitation, the net sales, profitability, and growth of Esperion’s commercial products, clinical activities and results, supply chain, commercial development and launch plans, the outcomes and anticipated benefits of legal proceedings and settlements, and the risks detailed in Esperion’s filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438


FAQ

When will Robert Hoffman become Audit Committee Chairperson at Esperion (ESPR)?

Robert Hoffman will become Chairperson of the Audit Committee at Esperion effective May 29, 2025.

Which board members are leaving Esperion (ESPR) and when?

Nicole Vitullo and Antonio M. Gotto, Jr., M.D., D. Phil. will step down from Esperion's board effective June 1, 2025.

What is Robert Hoffman's most recent executive experience before joining ESPR's board?

Hoffman served as President, CEO, interim CFO and Chairperson of Kintara Therapeutics from 2021 to 2024.

What other companies' boards does Robert Hoffman currently serve on?

Robert Hoffman currently serves on the boards of TuHURA Biosciences and Fibrobiologics.
Esperion Therape

NASDAQ:ESPR

ESPR Rankings

ESPR Latest News

ESPR Stock Data

233.04M
195.41M
1%
65.72%
14.73%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
ANN ARBOR